|
Canada-0-LABORATORIES कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Effects of lipid and mRNA concentrations and mRNA size on payload . . .
The IVIS images of mice and harvested livers and spleens at 12 h post-i v injection of LNP formulations at an mRNA dose of 0 5 mg mRNA kg
- Development of Lipid Nanoparticle Formulation for the Repeated . . .
A dose of 0 5 mg kg LNP encapsulating hEPO mRNA was delivered intravenously into a 7-week-old female Balb c mouse and evaluated 6 h later using the hEPO ELISA kit
- Protocol for the development of mRNA lipid nanoparticle vaccines and . . .
Here, we present a protocol for the development of mRNA-loaded lipid nanoparticle (LNP) vaccines for target antigen sequences of interest We describe key steps required to design and synthesize mRNA constructs, their LNP encapsulation, and mouse immunization
- Lipid nanoparticles for mRNA delivery - Nature Reviews Materials
In this Review, we discuss the design of lipid nanoparticles for mRNA delivery and examine physiological barriers and possible administration routes for lipid nanoparticle–mRNA systems
- Studying how administration route and dose regulates antibody . . .
In conclusion, the experiment demonstrated that administration of high LNP doses (0 3 mg kg mRNA) through the subcutaneous route leads to a significantly higher generation of anti-LNP IgM than intravenous and intramuscular injections
- Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid . . . - JoVE
Dilute the mRNA-LNP solution with sterile 1x PBS so that 2 µg of total mRNA is present in a 100 µL tail vein injection volume, which corresponds to a body weight dose of approximately 0 1 mg kg for a 20 g mouse
- Versatility of LNPs across different administration routes for targeted . . .
In this review, we summarize recent studies that highlight the versatility of LNPs, through optimization for delivery across different routes of administration, while scrutinizing the route-dependent formulation strategies
- Lipid nanoparticles deliver mRNA to the blood–brain barrier
Here we report methods to isolate different cell types from the CNS, and subsequently present mRNA delivery readouts using a liver-detargeted LNP These data suggest that LNPs without targeting ligands can transfect cerebral endothelial cells in mice after intravenous administration
- 1275 Optimizing lipid nano-particle (LNP) design for mRNA drug delivery . . .
In case study 2, we predicted the optimal formulation for a hypothetical LNP-mRNA given intravenously to maximize the bioavailability in Lung Furthermore, we simulate different dosing strategies and their effect on drug efficacy
- Minimizing the ratio of ionizable lipid in lipid nanoparticles for in . . .
In this study, we synthesized a series of ionizable lipids, denoted as HTO, with a higher count of hydroxyl groups compared to SM-102 Remarkably, LNPs based on HTO12 lipid demonstrated comparable mRNA delivery efficiency and biosafety to those based on SM-102
|
|